Qorvo® Biotechnologies Omnia™ SARS-CoV-2 Antigen Test Detects Delta and Other Circulating Variants in Two StudiesRead More
Qorvo® Biotechnologies Omnia™ SARS-CoV-2 Antigen Test Platform Validated in National Institutes of Health (NIH) Funded StudyRead More
Qorvo® Biotechnologies Awarded $24.4 Million National Institutes of Health Contract to Scale Point-of-Care COVID-19 Antigen TestingRead More
Qorvo Biotechnologies Omnia™ SARS-CoV-2 Antigen Test Detects Delta and Other Circulating COVID-19 VariantsRead the White Paper
Qorvo Biotechnologies Omnia™ Instrument and SARS-CoV-2 Antigen Test Completes Independent Verification from the National Institute of Health (NIH) as Part of the Rapid Acceleration of Diagnostics (RADx) InitiativeRead the White Paper
Qorvo Biotechnologies In The News
The Tech Poised to Usher in a New Era in
Download necessary documents such as test cartridge Instructions for Use, the Qorvo Omnia Instrument Operating Manual, Quick Start Guides and Safety Datasheets (SDS).
Qorvo BAW Technology
Learn how Qorvo Bulk Acoustic Wave (BAW) technology is revolutionizing the diagnostic testing landscape.
About Qorvo Biotechnologies
Qorvo Biotechnologies, LLC is a wholly owned subsidiary of Qorvo, Inc. focused on the development of point-of-care (POC) diagnostics solutions leveraging Qorvo’s innovative BAW sensor technology.
Qorvo makes a better world possible by providing innovative radio frequency (RF) solutions at the center of connectivity. We combine product and technology leadership, systems-level expertise and global manufacturing scale to quickly solve our customers’ most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including advanced wireless devices, wired and wireless networks, and defense radar and communications. We also leverage unique competitive strengths to advance 5G networks, cloud computing, the Internet of Things and other emerging applications that expand the global framework interconnecting people, places and things.